An allocation by random phase II/III trial of doxycycline in comparison to standard therapy in newly-diagnosed cardiac AL amyloidosis patients with bortezomib-based therapy An allocation by random phase II/III trial of doxycycline in comparison to standard therapy in newly ...
A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy - ReDox A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed ca ...
Light chain (AL) amyloidosis is a protein conformational disease, caused by a small bonemarrow plasma cell clone producing light chains (LCs) that undergo conformational changes,aggregate and deposit in tissues in the form of amyloid fibrils. This process causes dysfunctionof the organs involved and leads to death if not effectively treated.;Therapeutic area: Not possible to specify Light chain (AL) amyloidosis is a protein conformational disease, caused by a small bonemarrow plasm ...